Opinion
Video
Author(s):
The panel shares clinical practices for overcoming immunotherapy resistance in patients with non-small cell lung cancer.
Video content above is prompted by the following questions:
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity